Intravenous artesunate is the cornerstone treatment for cerebral malaria, having replaced quinine after large trials showed it cuts death rates by roughly a fifth to a third depending on the patient’s age. But killing the parasite is only part of the challenge. Cerebral malaria triggers a cascade of brain swelling, seizures, metabolic crises, and vascular damage that each demand their own management, and several once-promising interventions have turned out to be useless or harmful. Getting the full picture of how clinicians actually manage this disease requires looking well beyond the antimalarial drug itself.
What Makes Cerebral Malaria So Dangerous
Unlike many infections that invade the brain directly, the malaria parasite does not cross into brain tissue. Instead, red blood cells infected with Plasmodium falciparum become sticky and lodge in the tiny blood vessels of the brain, a process called sequestration. This clogs and sometimes ruptures vessels in both the cerebrum and the cerebellum, starving surrounding tissue of oxygen and triggering intense local inflammation.1PubMed Central. Immunopathology of cerebral malaria: morphological evidence of parasite sequestration in murine brain microvasculature The blood-brain barrier, which normally keeps large molecules and immune cells out of brain tissue, breaks down in the process. That breakdown allows hemorrhages and swelling that drive many of the neurological symptoms, from coma to seizures to lasting brain injury.2PubMed Central. Cerebral malaria: mysteries at the blood-brain barrier
Confirming the Diagnosis With Retinopathy
Coma in a child with malaria parasites in the blood is not always cerebral malaria. Other infections can cause coma, and malaria parasitemia is so common in endemic areas that a child might have both malaria and bacterial meningitis at the same time. A major diagnostic advance came from the discovery that a specific pattern of changes in the retina, visible through an ophthalmoscope, is highly specific to true malarial coma. This malarial retinopathy includes patchy whitening of the retina and focal color changes in retinal blood vessels, features not seen in other causes of childhood coma.3PubMed Central. Redefining cerebral malaria by including malaria retinopathy A large autopsy study in Malawi found that retinopathy was better than any other clinical or laboratory feature at distinguishing malarial from non-malarial coma.4PubMed Central. Malarial retinopathy: a newly established diagnostic sign in severe malaria This matters for treatment decisions because a misdiagnosed child may receive artesunate when they actually need antibiotics for meningitis, or vice versa.
Artesunate Over Quinine
For decades, intravenous quinine was the standard drug for severe malaria. That changed after two landmark trials. In adults, predominantly from Southeast Asia, artesunate reduced the risk of death by about 39% compared with quinine. In African children, the reduction was about 22%, with roughly 8.5% of artesunate-treated children dying versus nearly 11% of those given quinine.5PubMed Central. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial A Cochrane review pooling data from multiple trials confirmed the benefit across both age groups.6PubMed Central. Artesunate versus quinine for treating severe malaria Artesunate also has practical advantages: it can be given as a quick intravenous push rather than a slow infusion, it causes less hypoglycemia than quinine, and it is now widely available through WHO prequalification programs.
The World Health Organization now recommends intravenous artesunate as the first-line treatment for all severe malaria, including cerebral malaria, in both adults and children. Where intravenous access is not immediately available, intramuscular artesunate or rectal artesunate suppositories serve as a bridge to get the drug into the patient while they are transported to a facility capable of full care.
Brain Swelling and Why It Kills
Brain swelling is the most immediate threat to life in pediatric cerebral malaria. MRI studies of children in Malawi showed that among those who died, 84% had severe brain swelling at admission, compared with about 27% of survivors.7PubMed Central. Brain swelling and death in children with cerebral malaria When the brain swells enough, it herniates through the base of the skull, compressing the brainstem and stopping breathing. This is the most common immediate cause of death in children with cerebral malaria.
Despite the clear link between swelling and death, treating it effectively has proved frustratingly difficult. A recent randomized trial in Malawi tested two interventions in children with highly increased brain volume: mechanical ventilation and intravenous hypertonic saline. Neither reduced seven-day mortality compared with usual care. Hypertonic saline did increase blood flow velocity in major brain vessels, but in children who already had excessive blood flow to the brain at baseline, it actually worsened outcomes, roughly tripling the risk of death or neurological damage compared with usual care.8PubMed. Adjunctive Mechanical Ventilation or Intravenous Hypertonic Saline in Malawian Children with Cerebral Malaria and Highly Increased Brain Volume: A Randomized, Phase 3 Clinical Trial This finding underscores how dangerous it can be to transplant treatments that work in other forms of brain edema, such as traumatic brain injury, without testing them specifically in malaria.
Non-invasive monitoring of intracranial pressure is an area of active interest, especially in resource-limited settings where the invasive monitors used in high-income neurocritical care units are unavailable.9PubMed Central. Management and monitoring strategies for severe cerebral malaria: a guide for the intensivist Optic nerve sheath diameter measured with bedside ultrasound is one promising approach being evaluated.
Controlling Seizures Without Causing Harm
Seizures are extremely common in pediatric cerebral malaria. For years, phenobarbital was the go-to drug because it was cheap, widely available, and effective at suppressing seizure activity. The problem is that at the dose needed to prevent seizures in cerebral malaria, phenobarbital roughly doubled the risk of death, likely by suppressing breathing. One trial found mortality was 18% in the phenobarbital group versus 8% in children who received a placebo, and the risk of death skyrocketed when phenobarbital was combined with multiple doses of diazepam.10PubMed. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study A Cochrane review of three trials confirmed the pattern: fewer seizures, but more deaths.11PubMed Central. Routine anticonvulsants for treating cerebral malaria
This left clinicians in a bind. Repeated seizures worsen brain injury, but the most accessible anticonvulsant was killing patients. Levetiracetam, a drug widely used for epilepsy in high-income countries, has emerged as a safer alternative. In a trial of comatose children with cerebral malaria, enteral levetiracetam was rapidly absorbed, reached therapeutic levels within four hours in 90% of children, and achieved seizure freedom in all seven children who received it as initial therapy. Compared with phenobarbital, it was significantly safer, with none of the respiratory depression that plagued phenobarbital.12PubMed Central. A clinical trial of enteral Levetiracetam for acute seizures in pediatric cerebral malaria Larger trials are still needed, but for hospitals that have access to it, levetiracetam offers a way out of the seizure-versus-respiratory-failure dilemma.
Metabolic Crises That Compound Brain Injury
Two metabolic problems deserve specific attention in cerebral malaria: low blood sugar and lactic acidosis. Both are more pronounced in fatal cases. Children who died in a study from the Gambia had admission blood glucose levels averaging about 3.2 mmol/L compared with 5.8 mmol/L in survivors, and their blood lactate levels were nearly double those of children who lived.13Transactions of the Royal Society of Tropical Medicine and Hygiene. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance Quinine itself worsens hypoglycemia by stimulating insulin release, which is one more reason artesunate has replaced it. Children treated with quinine had significantly more episodes of low blood sugar after admission than those given artemisinin-based drugs.
Lactic acidosis reflects tissue oxygen starvation. When parasitized red blood cells block tiny vessels, surrounding tissue switches to anaerobic metabolism and pumps out lactate. Persistently elevated lactate four hours after admission turned out to be the single best predictor of death in one large series. Practically, this means regular glucose monitoring and dextrose supplementation are essential parts of cerebral malaria care, alongside lactate measurement where available to help identify patients at highest risk.
Bacterial Coinfection and the Case for Empirical Antibiotics
Children with cerebral malaria frequently harbor bacterial bloodstream infections at the same time, and no clinical or laboratory test can reliably distinguish cerebral malaria alone from cerebral malaria with a bacterial coinfection. A systematic review found that among African children with falciparum malaria and concurrent bacteremia, gut-derived gram-negative organisms were overrepresented, with non-typhoidal Salmonella being the most common.14PubMed Central. Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review
A recent prospective study of children in febrile coma in Malawi concluded that immediate parenteral antibiotics alongside artesunate should be given to all children with severe malaria and altered consciousness, regardless of retinopathy status. The researchers estimated that adhering to this approach across the continent could save more than 20,000 children per year who have cerebral malaria with undetected bacterial coinfection.15The Lancet Global Health. Causes, risk factors for mortality, and long-term neurosequelae of children in febrile coma in Malawi: a prospective cohort study WHO guidelines already recommend this dual approach, but adherence in the field remains inconsistent.
Blood Transfusion and Exchange Transfusion
Severe malaria destroys red blood cells, and profound anemia compounds brain oxygen starvation. WHO guidelines recommend blood transfusion when hemoglobin drops below certain thresholds, but animal research suggests benefit may extend to patients with hemoglobin levels above the usual trigger when signs of organ hypoperfusion or elevated lactate are present.16Scientific Reports. Whole blood transfusion improves vascular integrity and increases survival in artemether-treated experimental cerebral malaria Randomized trials in humans are still needed to define the right threshold, balanced against risks of transfusion reactions and infection transmission.
Exchange transfusion, which removes a patient’s blood and replaces it with donor blood to lower parasite counts rapidly, has been used in imported severe malaria cases in high-income countries. A retrospective study found it was safe and improved liver function and coagulation markers but did not improve parasite clearance or overall outcomes compared to artesunate alone.17PubMed Central. Manual exchange transfusion for severe imported falciparum malaria: a retrospective study A separate case series using automated exchange with the COBE Spectra system reported that all patients tolerated the procedure well, with five cerebral malaria patients regaining full consciousness within three days.18PubMed Central. Exchange transfusion combined with artesunate (ET-AS) as a safe and effective therapy in severe P. falciparum malaria: a case series Exchange transfusion remains a niche intervention, mostly available in well-equipped referral hospitals.
Adjunctive Therapies That Failed
Because the brain injury in cerebral malaria involves intense inflammation, corticosteroids seemed like a logical addition to antimalarial treatment. They are not. A double-blind trial of dexamethasone in 100 comatose patients found that it actually prolonged coma and more than doubled the rate of complications such as pneumonia and gastrointestinal bleeding.19PubMed. Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients A Cochrane review concluded there is no evidence of benefit from corticosteroids in cerebral malaria.20Cochrane Database of Systematic Reviews. Corticosteroids for treating cerebral malaria This is worth knowing because the reflex to “reduce inflammation with steroids” is so deeply ingrained in medical training that the question still comes up.
The list of other interventions tested and found wanting includes mannitol (which can worsen outcomes in certain subgroups, as discussed with brain swelling above), heparin, iron chelators, and several others. The repeated failure of adjunctive therapies in cerebral malaria reflects how poorly understood the mechanisms of brain injury still are, and how interventions that seem rational on paper can backfire in the specific vascular and inflammatory environment of this disease.
Neuroprotective Research on the Horizon
The research community has shifted toward agents that target the host’s response rather than the parasite itself. Among the more promising leads are drugs that activate a receptor called PPARγ, which is involved in inflammation control and tissue repair. In a mouse model of cerebral malaria, adding a PPARγ-activating drug to standard antimalarial treatment reduced blood vessel activation in the brain, boosted protective antioxidant enzymes, and increased levels of brain-derived neurotrophic factor. Two months later, mice that received the adjunctive therapy had normal cognitive function, while those treated with antimalarials alone had measurable cognitive deficits and brain shrinkage.21PLoS Pathogens. PPARγ Agonists Improve Survival and Neurocognitive Outcomes in Experimental Cerebral Malaria and Induce Neuroprotective Pathways in Human Malaria Other investigational approaches include drugs that boost nitric oxide levels, immune modulators like rosiglitazone, and agents that interfere with the sticking of infected red blood cells to vessel walls.22PubMed Central. Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria Researchers have also proposed repurposing drugs developed for cancer and neurological disease to stabilize endothelial cells in the brain during malaria.23PubMed. Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria None of these has reached large-scale human trials yet, but the shift from “kill the parasite faster” to “protect the brain while the parasite is being killed” marks an important evolution in how the field thinks about treatment.
How the Disease Differs in Children and Adults
Cerebral malaria is not a single uniform condition. Brain MRI studies comparing pediatric and adult patients have revealed strikingly different injury patterns. In children who survive, the hallmark finding is oxygen-deprivation damage in the deep and subcortical white matter. In surviving adults, a similar type of damage concentrates instead in the basal ganglia, the deep gray matter structures involved in movement and cognition. The fatal end-stage patterns also diverge: children die primarily from massive brain swelling that herniates the brainstem, while adults with fatal disease show evidence of widespread oxygen starvation across the whole brain, accompanied by elevated blood markers of tissue injury.24Clinical Infectious Diseases. Brain Magnetic Resonance Imaging Reveals Different Courses of Disease in Pediatric and Adult Cerebral Malaria
These differences have real implications for management. The brain-swelling-driven death in children means that anything targeting intracranial pressure has the greatest potential payoff in pediatric patients. The global ischemia pattern in adults may instead call for strategies that improve blood flow or protect neurons from oxygen deprivation. Treating “cerebral malaria” as a single entity when designing clinical trials may partly explain why so many adjunctive therapies have failed: they may help one age group while doing nothing, or harm, in another.
The Threat of Artemisinin Resistance
Artesunate’s dominance as first-line treatment makes any erosion in its effectiveness deeply concerning. In parts of Southeast Asia, parasites have developed delayed clearance in response to artemisinin-based drugs. Modeling work has shown that in resistant parasites, the initial dose of artesunate can be rendered nearly or completely ineffective because the drug’s presence coincides with a life-cycle stage where the parasite is insensitive to it.25The Journal of Infectious Diseases. Optimal Treatments for Severe Malaria and the Threat Posed by Artemisinin Resistance So far, artemisinin resistance has not established itself in Africa, where the overwhelming majority of cerebral malaria occurs. But if it does, the consequences would be severe, since there is no comparably effective replacement drug waiting in the wings. Quinine remains available as a fallback, but its inferiority to artesunate is well documented, and the logistical demands of slow intravenous quinine infusions are poorly suited to the under-resourced hospitals where most cerebral malaria is treated.
Long-Term Neurological Consequences in Survivors
Surviving cerebral malaria is not the same as recovering from it. Children who survive face substantially elevated risks of epilepsy, cognitive impairment, behavioral problems, and other neurological disabilities. A meta-analysis found the odds of developing epilepsy after cerebral malaria were roughly four to five times higher than in control children, and the odds of behavioral disorders were about eight times higher.26Transactions of The Royal Society of Tropical Medicine and Hygiene. Cerebral malaria as a risk factor for the development of epilepsy and other long-term neurological conditions: a meta-analysis These outcomes make cerebral malaria a leading cause of childhood neurodisability in the regions where it is most common.27PubMed Central. Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome
Blood markers may eventually help predict which children are headed for cognitive trouble. Plasma tau, a protein released when neurons are damaged, has been linked to long-term outcomes. In children under five at the time of their cerebral malaria episode, higher admission tau levels were associated with worse overall cognition during follow-up, along with specific deficits in attention and working memory once the children reached school age.28JAMA Network Open. Association of Plasma Tau With Mortality and Long-term Neurocognitive Impairment in Survivors of Pediatric Cerebral Malaria and Severe Malarial Anemia If validated further, markers like tau could help identify children who need early cognitive rehabilitation, speech therapy, or educational support, interventions that are rarely available in malaria-endemic regions but that could meaningfully change a child’s trajectory if delivered in the critical early years after the illness.